Last €0.03 EUR
Change Today -0.005 / -16.13%
Volume 0.0
As of 2:23 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

genetic technologies ltd (DU8) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/15 - €0.07
52 Week Low
10/6/14 - €0.0030
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENETIC TECHNOLOGIES LTD (DU8)

genetic technologies ltd (DU8) Related Bloomberg News

View More Bloomberg News

genetic technologies ltd (DU8) Related Businessweek News

No Related Businessweek News Found

genetic technologies ltd (DU8) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders. The company also provides DNA based tests comprising peace of mind paternity, legal paternity, antenatal DNA, deceased estate, DNA profiling, grandparent, immigration, sibling, twins, and Y-chromosome DNA tests. In addition, it offers DNA testing, canine health register, forensics, and breed identification services to animals. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited is headquartered in Fitzroy, Australia.

genetic technologies ltd (DU8) Top Compensated Officers

Chief Executive Officer, Chief Operating Offi...
Total Annual Compensation: A$14.4K
Director of Global Licensing & Intellectual P...
Total Annual Compensation: A$140.4K
Scientific Director
Total Annual Compensation: A$125.7K
Quality and Business Operations Director
Total Annual Compensation: A$98.7K
Compensation as of Fiscal Year 2014.

genetic technologies ltd (DU8) Key Developments

Genetic Technologies Limited Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Genetic Technologies Limited reported consolidated earnings results for the year ended December 31, 2014. Revenue from continuing operations - genetic testing services was $1.3 million against $2.0 million last year. Loss from continuing operations before income tax expense was $4.8 million against $5.1 million last year. Loss attributable to owners of the company was $4.8 million or $0.68 per basic and diluted share against $5.1 million or $1.01 per basic and diluted share last year. Net cash flows used in operating activities was $5.8 million against $5.2 million last year. Purchase of property, plant and equipment was $0.2 million against $0.02 million last year.

Genetic Technologies Limited Appoints Eutillio Buccilli as Chief Executive Officer

Genetic Technologies Limited announced that Mr. Eutillio Buccilli has been appointed Chief Executive Officer of the Company following the resignation of Ms. Alison Mew which was effective 31 December 2014. Mr. Buccilli joined the Company in June 2014 as the Chief Financial Officer and was appointed to the position of Chief Operating Officer and Chief Financial Officer in late 2014. He has more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with General Electric, Computer Science Corporation, Coles Myer and Challenger Limited. Whilst at GE, Mr. Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut.

Genetic Technologies Limited Announces 6 New Breast Centres to Begin Offering BREVAGenplus

Genetic Technologies Limited reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. Prior to the release of BREVAGenplus, the Company revised its sales strategy to focus on large comprehensive breast treatment and imaging centres, in concert with its ongoing approach to independent physician and women’s healthcare providers. This recent pivotal change of sales and marketing emphasis towards large breast centres, which are more complex entities with a longer sales cycle, but with higher potential, is expected to lead to significant acceleration in growth and less volatile test volumes than the Company has experienced to date.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.03 EUR -0.005

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $42.70 USD +0.49
Sonic Healthcare Ltd A$19.39 AUD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation DU8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.2x
Price/Book 103.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at